sotatercept
Sign in to saveAlso known as ACE-011, MK-7962-020
Sotatercept, sold under the brand name Winrevair, is a medication used to treat pulmonary arterial hypertension. It inhibits activin signaling using the extracellular domain of the activin type 2 receptor fused with an immunoglobulin Fc domain (ACTRIIA-Fc) as a recombinant fusion protein. It is administered via subcutaneous injection.
In the Vinony graph
Within Vinony's link graph, sotatercept is referenced by 179 other articles, and connects out to medication, headache and diarrhea.
Vinony files it under Antihypertensive agents, Chemical pages without ChemSpiderID and Drugs developed by Merck & Co..
Its subject is documented across 5 Wikipedia language editions.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- Admin. routes
- parenteral
- Indications
- multiple myeloma, anemia (phenotype), pulmonary arterial hypertension, myelofibrosis
via ChEMBL · EBI
Clinical Trials
40 registered- PHASE3TERMINATEDStudy of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · NCT04811092
- PHASE2WITHDRAWNA Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple MyelomaRebecca Silbermann · NCT02230917
- PHASE2COMPLETEDStudy of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)Merck Sharp & Dohme LLC · NCT01736683
- PHASE3COMPLETEDA Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)Merck Sharp & Dohme LLC · NCT05818137
- NO_LONGER_AVAILABLEExpanded Access for ACE-011Celgene · NCT03724227
- PHASE2COMPLETEDSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaM.D. Anderson Cancer Center · NCT01712308
Wikidata facts
- Instance of
- fusion protein
Show 3 more facts
- route of administration
- subcutaneous injection
- chemical formula
- C₃₄₄₈H₅₂₆₄N₉₂₀O₁₀₅₈S₄₂
- medical condition treated
- pulmonary hypertension
via Wikidata · CC0
~4 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Side effects
- History
- Society and culture
- Economics
- Names
- Research
- References
- Further reading
- External links
Sotatercept, sold under the brand name Winrevair, is a medication used to treat pulmonary arterial hypertension. It inhibits activin signaling using the extracellular domain of the activin type 2 receptor fused with an immunoglobulin Fc domain (ACTRIIA-Fc) as a recombinant fusion protein. It is administered via subcutaneous injection.
The most common side effects include headache, epistaxis (nosebleed), rash, telangiectasia (spider veins), diarrhea, dizziness, and erythema (redness of the skin).
Excerpted from Wikipedia’s “sotatercept” article, available under the CC BY-SA 4.0 licence.